Firm at a glance
Arsenal Capital Partners is a platform private equity firm that has raised more than $10 billion in institutional funds, per its website [S1].
What they buy
Arsenal Capital Partners demonstrates a concentrated focus on healthcare businesses, particularly pharmaceutical services companies, according to its public portfolio [S2]. The firm’s holdings span pharma services, healthcare technology, diagnostics, medical devices, and healthcare services. Recent acquisitions outside healthcare include industrial companies such as Velcro Companies and ThermoSafe, suggesting the firm operates across multiple sectors [S3].
Portfolio
Healthcare – Pharma Services
3DR Labs, BioIVT, CellCarta, Certara, Endpoint, Lumanity, Neovance, Priority Solutions, Rancho BioSciences, Scientific Protein Laboratories, and WCG [S2].
Healthcare – Healthcare Technology
Knowtion Health (acquired August 2024), OncoHealth, and TractManager [S2][S3].
Healthcare – Diagnostics
Epic Sciences [S2].
Healthcare – Healthcare Services
Hopebridge [S2].
Healthcare – Medical Devices
Innovative Medical Device Solutions [S2].
Recent activity (last 24 months)
* Velcro Companies acquisition, May 26, 2026 [S3]
* ATP exit, April 1, 2026 [S3]
* MaxHealth exit, February 13, 2026 [S3]
* ThermoSafe acquisition, November 3, 2025 [S3]
* APPLIED Adhesives exit, April 15, 2025 [S3]
* Knowtion Health acquisition, August 22, 2024 [S3]
* Endpoint Clinical and Patient Access Businesses acquisition, June 4, 2024 [S3]
How this firm fits a seller
Arsenal Capital Partners appears to pursue both platform acquisitions and exits with regularity, having completed three exits and four acquisitions in the past 24 months per public sources [S3]. The firm’s healthcare portfolio concentration, particularly in pharmaceutical services, suggests it may offer sector expertise and buy-and-build strategies for businesses serving drug development and clinical research markets. Sellers in healthcare technology, diagnostics, or pharma services may find Arsenal an appropriate fit given the depth of its existing portfolio in these subsectors [S2]. The firm’s recent exit activity indicates an active realization strategy for portfolio companies.
Sources
[S1] https://www.arsenalcapital.com (as of 2026-07-07)
[S2] https://www.arsenalcapital.com/healthcare/portfolio (as of 2026-07-07)
[S3] https://www.arsenalcapital.com/news (as of 2026-07-07)
Frequently asked questions
Does Arsenal Capital Partners buy Healthcare – Pharma Services businesses?
Yes, pharmaceutical services represents Arsenal’s most active healthcare subsector, with at least 11 portfolio companies including WCG, Certara, BioIVT, Lumanity, and Scientific Protein Laboratories, per its website [S2]. The firm acquired Endpoint’s clinical and patient access businesses in June 2024 [S3].
What companies has Arsenal Capital Partners acquired recently?
Arsenal Capital Partners acquired Velcro Companies in May 2026, ThermoSafe in November 2025, and Knowtion Health in August 2024, according to its news page [S3]. The firm also acquired Endpoint’s clinical and patient access businesses in June 2024 [S3].
Where is Arsenal Capital Partners based and how big is the firm?
Arsenal Capital Partners has raised more than $10 billion in institutional funds, per its website [S1]. The firm’s headquarters location was not disclosed in available public sources as of July 2026.
Is Arsenal Capital Partners still actively acquiring?
Yes, Arsenal Capital Partners completed its most recent acquisition of Velcro Companies in May 2026 and has completed four acquisitions in the past 24 months, indicating active deal activity [S3].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.